Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn about a paper by Frederick Locke et al. published in the Journal of Clinical Oncology:

“Advancing CAR T-Cell Therapy: Off-the-Shelf Allogeneic Approach.

The ALPHA/ALPHA2 studies evaluated the allogeneic CD19 CAR T-cell product cema-cel in relapsed/refractory large B-cell lymphoma (R/R LBCL) – offering a potential off-the-shelf alternative to autologous CAR T-cell therapy.

Key Findings:

Promising efficacy: 58% overall response rate (ORR), 42% complete response rate (CRR)
CAR T expansion observed post-infusion, with persistence up to 4 months
Manageable safety profile: No cases of GVHD, ICANS, or grade ≥3 CRS
Median duration of CR: 23.1 months

These results highlight cema-cel’s potential to improve accessibility and efficacy in LBCL treatment! Further studies are warranted to solidify its role in the next-gen immunotherapy landscape.”

“Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies”

Authors: Frederick Locke, Javier Munoz, Michael Tees, John Le Gall, Sattva Neelapu et al.

Yan Leyfman: Advancing CAR T-Cell Therapy - Off-the-Shelf Allogeneic Approach

Yan Leyfman: Advancing CAR T-Cell Therapy – Off-the-Shelf Allogeneic Approach